Hu Pei, MD, is Professor of Clinical Pharmacology and Director, Phase I Unit, Beijing Key Laboratory of Clinical PK/PD, Clinical Pharmacological Research Center, Peking Union Medical College Hospital. She has engaged in the teaching and research of clinical pharmacology, primarily in early clinical research and quantitative pharmacology of new drugs, for two decades. Professor Pei previously engaged in postdoctoral research at the Department of Medicinal Chemistry, University of Washington (US) through funding from the US National Institutes of Health Fogarty Fellowship, and has published more than 70 peer-reviewed articles. She earned her Doctorate in Medicine from Peking Union Medical College.

Xia Jie Lai, PhD, serves as Director, Professor, and Doctoral Tutor of the Department of Health Statistics at the Air Force Military Medical University (Fourth Military Medical University), and as biostatistics review and consultation expert for the State Food and Drug Administration. He has contributed to dozens of clinical trials for chemical drugs, Chinese medicine, biological products, and medical devices; his current work includes statistical design and analysis of large-scale clinical trials for vaccines. Dr. Lai’s work has been funded through seven National Natural Science Foundation projects, and he participated in three research projects in the Eleventh Five-Year Plan for Science and Technology Innovation.

Dr. Ling Su is a Research Fellow in Shengyang Pharmaceutical University Yeehong Business School and a Venture Partner in Lilly Asia Ventures (LAV). He has 30 years of experience in drug regulatory and development. He had worked in various R&D management positions in the pharma industry, including Medical Director at MSD, Pharma Development Director at Roche, VP for Clinical Research Asia Pacific at Wyeth, and SVP and Head of Pharma Development China at Novartis. Prior to that, he worked in the Chinese regulatory agency and CDER, US FDA. He is a Fellow of DIA and was the President of DIA (2012-2013). Ling holds BS in pharmacology from Shanghai Medical University and PhD in Epidemiology from University of North Carolina at Chapel Hill, USA.

Sunny Zhu, MD, serves as Chief Medical Officer at Everest Medicines. She previously served as Global Clinical Lead for anti-infectives in Global Clinical Development for Bayer Healthcare Company. Before this role, Dr. Zhu had served as Executive Director, Development Projects & Portfolio Management, responsible for the development strategy and its execution for AstraZeneca’s new product pipeline and portfolio. Dr. Zhu has contributed to more than 40 new drug development projects across numerous therapeutic areas, and has served as Clinical Research Manager for China, Clinical Development Director for Asia-Pacific, and Global Project Manager for Global Product Teams. She earned her Medical Degree from Peking University Medical School.

Dr. Rui Chen is the director of Phase I ward in Peking Union Medical College Hospital (PUMCH). Dr. Chen studied at Biology Department in Tsinghua University and completed this premedical stage of learning with high grades. Then she studied in Peking Union Medical College and received the Degree of Medical Doctor (M.D.) in clinical medicine. Then she obtained a master’s degree in Pharmacometrics from University of Manchester in the United Kingdom. She also completed the Roche-PUMCH fellowship program in clinical pharmacology after several rotations in industry.